

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

			www.uspto.gov		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/020,638	12/14/2001	Bodan Ma	1979.EEM	9225	
	590 03/12/2003				
	Jane E. Gennaro Assistant General Counsel, I.P.			EXAMINER	
NATIONAL ST 10 Finderne Av	NATIONAL STARCH AND CHEMICAL COMPANY 10 Finderne Avenue		MITCHELL, JAMES M		
Bridgewater, NJ 08807-0500			ART UNIT	PAPER NUMBER	
			2827		

DATE MAILED: 03/12/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
-	Office Action 2	10/020,638	MA ET AL.
ž.	Office Action Summary	Examiner	Art Unit
		James Mitchell	2827
Period fo	The MAILING DATE of this communic or Reply	cation appears on the cover sh	eet with the correspondence address
- Exte after - If the - If NC - Failu - Any r	ORTENED STATUTORY PERIOD FO MAILING DATE OF THIS COMMUNIO nsions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this commu period for reply specified above is less than thirty (30) period for reply is specified above, the maximum stative to reply within the set or extended period for reply weeply received by the Office later than three months afford patent term adjustment. See 37 CFR 1.704(b).	ATION, f 37 CFR 1.136(a). In no event, however, nication. days, a reply within the statutory minimun utory period will apply and will expire SIX (iii).	may a reply be timely filed n of thirty (30) days will be considered timely. 6) MONTHS from the mailing date of this communication
1)	Responsive to communication(s) file	d on 19 November 2002	
2a) <u></u>	Manual at the state of the stat	D)⊠ This action is non-final.	
3)	- -		
•	closed in accordance with the practic	e under <i>Ex parte Quayle</i> , 193	al matters, prosecution as to the merits is 35 C.D. 11, 453 O.G. 213.
4)⊠	Claim(s) <u>1-12</u> is/are pending in the ap	pplication.	
	a) Of the above claim(s) is/are	withdrawn from consideration	٦.
	Claim(s) is/are allowed.		
6)⊠	Claim(s) <u>1-5 and 7-11</u> is/are rejected.		
7)🛛	Claim(s) <u>6 and 12</u> is/are objected to.		
8) 🔲 (Claim(s) are subject to restriction	on and/or election requiremen	f.
Application	n Papers		•
	he specification is objected to by the E		
10)∐ T	ne drawing(s) filed on is/are: a)	☐ accepted or b)☐ objected to	by the Examiner.
	Applicant may not request that any object	ion to the drawing(s) be held in a	hevance See 37 CED 1 05(a)
11)[[]	ne proposed drawing correction filed o	n is: a)∏ approved b)	disapproved by the Examiner.
12)[] TI	If approved, corrected drawings are require	red in reply to this Office action.	
<u> </u> (2 	ne oath or declaration is objected to by	the Examiner.	
	der 35 U.S.C. §§ 119 and 120		
13)L A	cknowledgment is made of a claim for	foreign priority under 35 U.S	.C. § 119(a)-(d) or (f).
	All b) Some * c) None of:		
	Certified copies of the priority dod	cuments have been received.	
	Certified copies of the priority doc	cuments have been received i	n Application No
	Copies of the certified copies of the application from the Internation the attached detailed Office action for		een received in this National Stage
14) 🗌 Ack	nowledgment is made of a claim for d	omestic priority under 35 LLS	not received. .C. § 119(e) (to a provisional application
a) L	I ne translation of the foreign language	age provisional application bo	a baan manaturat
TO)	mowledginent is made of a claim for c	lomestic priority under 35 U.S	S Deen received. C.C. §§ 120 and/or 121
coment(s)		•	50 ·
	f References Cited (PTO-892) f Draftsperson's Patent Drawing Review (PTO-9 on Disclosure Statement(s) (PTO-1449) Paper		ew Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)
	ν, το	······································	

Art Unit: 2827

DETAILED ACTION

Drawings

The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the B-stageable underfill comprising a combination of two chemical compositions must be shown or the feature(s) canceled from the claim(s). No new matter should be entered.

A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-5 and 7-11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It is unclear how the first composition is a liquid and cured. A cured composition is mutually exclusive from being a liquid.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/020,638

Art Unit: 2827

Claims 1-5 and 7-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Date et al. (US 2002/0084019).

Date discloses a portion of a chip wafer (1; Par. 0005, Lines 2-3) having a B-stageable underfill (5) comprising a combination of two chemical compositions (Par. 0003; Abstract), characterized in that the first composition (Agent A; *acrylic...*; Abstract comprising language encompasses excluding epoxy) has been cured (Par.0077) and the second composition (Agent B; *epoxy*; Abstract provides that B can contain any component not in A) is inherently uncured (Par. 0078, Lines 4-5); wherein the curing range (Par. 0078, Line3) of the second composition is higher by at least 30 degrees Celsius than the range than the first composition (Par,0077, Line 7) to allow the first composition to cure without curing the second composition; and the second composition is an epoxy compound and an imidazole/anhydride adduct (Par. 0037).

With respect to the wafer being silicon, examiner takes official notice that silicon is well known at the time the invention was made and that it would have been obvious to one of ordinary skill in the art at the time the invention was made to form the chip wafer of Date of silicon in order to form a wafer.

With respect to claims 1 and 7, Date does not appear to explicitly teach the process limitations of the first composition being for example a liquid and the second composition being dispersible or dissolvable in the first composition, because the product of Date inherently possesses the structural characteristics imparted by the process limitation. See In re Fitzgerald, Sanders, and Bagheri, 205 USPQ 594 (CCPA 1980).

Art Unit: 2827

Allowable Subject Matter

Claims 6 and 12 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The following is a statement of reasons for the indication of allowable subject matter: the prior art does not disclose or make obvious a first and second underfill composition combined where the second composition is imidazole/anyhdride adduct that is either a complex 1 part 1,2,4,5-benzenetetracarboxylic anhydride an 4 parts 2-phenyl-4-methylimidazole, or a complex 1 part 1,2,4,5-benzenetetracarboxylic dianhydride an 4 parts 2-phenyl-4-methylimidazole including all the limitations the parent claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James Mitchell whose telephone number is (703) 305-0244. The examiner can normally be reached on M-F 10:30-8:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David L. Talbott can be reached on (703) 305-9883. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3432 for regular communications and (703) 305-3230 for After Final communications.

Application/Control Number: 10/020,638

Art Unit: 2827

Page 5

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0956.

imm ℓ

March 7, 2003

DAVID E. GRAYBILL PRIMARY EXAMINER

JULE MY